Figure 3

Relative risk curves of the best biomarkers in CSII patients. In A, B and C, miRNAs miR-21, miR-183 and miR-494 were analyzed separately. In D, the combination of miR-21 and miR-183 was analyzed. In E, the combination of miR-21 and miR-494 was analyzed. In F, the miR-183 and miR-494 combination was analyzed. In G, the combination of the three miRNAs studied (miR-21, miR-183 and miR-494). The miRNA up-regulation is represent by dotted lines, and down-regulation is represented by a continuous line.